RxDoctor Payments Data

Heather Parsley, APRN

Family · Big Clifty, KYNPI 1891776738

Payments from drug & device makers

$1,168in general payments, 2019–2025

Across 58 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$403
  • Novo Nordisk$254
  • GSK$128
  • AstraZeneca$116
  • Bayer$79
  • Teva Pharmaceuticals USA, Inc.$38
  • plus $150 from 7 others

What the payments were for

  • Food & beverage$1,168100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,168 in reported general payments places this provider in the 65th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$24,691
Medicare patients
68
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$49,398
FarxigaDapagliflozin Propanediol43$35,384
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$23,214
OzempicSemaglutide21$18,528
Tresiba Flextouch U-200Insulin Degludec24$18,217
Tresiba Flextouch U-100Insulin Degludec13$12,413
Celecoxib39$2,218
Albuterol Sulfate HfaAlbuterol Sulfate58$2,138
Insulin Degludec Pen (U-200)Insulin Degludec12$1,540
Duloxetine Hcl72$1,319
Rosuvastatin Calcium100$912
Levothyroxine Sodium109$833
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$762
Lisinopril164$631
Metoprolol Succinate65$619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$116$35,38443 claims
GSKTrelegy Ellipta$128$23,21428 claims
Novo NordiskOzempic$254$18,52821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,374 family providers in Kentucky.

Other family in Big Clifty

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →